ArticleDrug development research2025

Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 Inhibitors.

Alexandria M Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.